"Drs. James Hansen and Jiangbing Zhou of the Yale School of Medicine have confirmed that as a single agent PAT-DX1 localizes into xenograft triple negative breast cancer (TNBC) tumors in mice. Mice with TNBC tumors were treated with systemic administration of PAT-DX1, and at varying time points afterwards tumors were excised and examined for the presence of PAT-DX1. Preliminary pharmacokinetic analysis indicates that PAT-DX1 exhibited significant tumor penetration 8 hours after administration."
Seems price sensitive to me? @gassed
Ann: Preliminary PAT-DX1 pharmacokinetics, page-3
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(14.3%) |
Mkt cap ! $6.172M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $155 | 51.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 34 | 30795208 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 22489307 | 15 |
View Market Depth
| Last trade - 10.06am 10/10/2024 (20 minute delay) ? |
| PAB (ASX) Chart |